Last updated: March 14, 2026
What is the drug associated with NDC 00121-1680?
NDC 00121-1680 corresponds to Tobramycin and Dexamethasone Ophthalmic Suspension. It is used for treating bacterial eye infections and inflammation. The drug combines an aminoglycoside antibiotic with a corticosteroid, targeting ocular conditions resistant to monotherapy.
Market Overview
Current Market Size and Sales Data
The ophthalmic antibiotics market was approximately USD 2.5 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4% through 2027. Tobramycin-based products account for roughly 40% of that segment, driven by extensive off-label use and longstanding clinical acceptance.
Key Competitors
Major competitors include:
- Tobradex (GlaxoSmithKline)
- Tobracort (Alcon)
- Tobramycin/dexamethasone (generic formulations, primarily compounded)
Market share is concentrated among these products, with generics increasingly capturing market segments.
Regulatory Status and Approval Timeline
The specific formulation in NDC 00121-1680 obtained FDA approval in 2015. Since then, it has been available as a branded product, with recent updates allowing additional formulations to expand indications.
Price Analysis
Current Pricing
Wholesale acquisition costs (WAC):
| Product |
Approximate Cost per Tube |
Notes |
| Branded Tobramycin/Dexamethasone |
USD 50 - USD 70 |
Premium pricing, often covered by insurance |
| Generic Tobramycin/Dexamethasone |
USD 20 - USD 40 |
Widely available, price varies by supplier |
Price Trends
Over the past five years, branded formulations have maintained high prices despite generic availability. Generic versions saw price reductions of 20-30%, but branded products remain at premiums due to branding and perceived quality.
Factors Influencing Price Movements
- Patent expiration timelines
- Competition from generics
- Insurance reimbursement policies
- Manufacturing costs
Market Projections (2023–2028)
Sales Volume Forecast
- Expected to grow at ~4% CAGR paralleling the ophthalmic antibiotics market.
- Penetration in emerging markets and expanding indications could increase volume by 15% over five years.
Pricing Outlook
- Generic prices will continue to decline, averaging USD 15-USD 25 per tube by 2028.
- Branded prices likely to stabilize or slightly increase (~2-3% annually) due to inflation and research investments.
Revenue Projections
| Year |
Projected Revenue (USD millions) |
Assumptions |
| 2023 |
USD 150 |
Current sales, steady market share |
| 2025 |
USD 165 |
Slight market expansion, price stabilization |
| 2028 |
USD 175 |
Increased volume, stable prices |
Risks and Opportunities
Risks
- Patent cliffs for branded products.
- Regulatory changes facilitating easier entry of generics.
- Pricing pressures from healthcare providers and insurers.
Opportunities
- Development of combination therapies or formulations with extended indications.
- Entry into emerging markets with growing ophthalmic disease prevalence.
- Adoption of biosimilar or novel delivery systems.
Key Takeaways
- NDC 00121-1680 is a generic or branded ophthalmic drug with a market largely driven by generics.
- Market size is approximately USD 150 million, with a steady CAGR of 4%.
- Price per unit varies from USD 20–70, with discounts expected on generics.
- Revenue projections indicate modest growth, emphasizing market maturation and price stabilization.
Frequently Asked Questions
1. What are the main drivers for this drug's market growth?
Market growth primarily hinges on increasing prevalence of ocular infections and inflammation, expansion into new geographic regions, and the continued adoption of generic formulations.
2. How do patent expirations impact pricing?
Patent expirations typically cause branded prices to decline sharply, with generics capturing larger market share and driving down retail costs.
3. What is the outlook for generic versions?
Generics will continue to dominate the market, with prices decreasing and sales volume increasing as access expands.
4. Are new formulations or indications expected?
Potential exists for formulations with extended release or broader indications, though regulatory approval may delay adoption.
5. How might insurance policies influence pricing?
Insurance reimbursement policies favor low-cost generics, putting pressure on branded product pricing and affecting overall revenue.
Sources:
[1] IQVIA. (2022). Ophthalmic Market Report.
[2] FDA. (2023). Approved Ophthalmic Drugs.
[3] Statista. (2023). Ophthalmic Drugs Market Revenue Forecast.
[4] Medi-Data. (2023). Pricing Trends in Ophthalmic Pharmaceuticals.
